BIOMAT Database Logo BIOMAT Database Logo

Controlled trial of dexamethasone and mannitol for the cerebral oedema of fulminant hepatic failure. 1982

J Canalese, and A E Gimson, and C Davis, and P J Mellon, and M Davis, and R Williams

A controlled trial of 44 patients was undertaken to evaluate the use of dexamethasone (32 mg stat, 8 mg qds) in preventing, and intravenous mannitol (1 g/kg) in reversing the cerebral oedema of fulminant hepatic failure. Diagnosis of cerebral oedema was based on intracranial pressure recordings or the presence of defined clinical signs. Cerebral oedema developed in 34 patients with similar frequency in those treated with and without dexamethasone (16 of 21 and 18 of 23 respectively). In those 34 patients episodes of cerebral oedema resolved significantly more frequently in the 17 patients who received mannitol than in the 17 patients who did not (44 of 53 and 16 of 17 respectively, p less than 0.001). Dexamethasone did not affect survival but among patients who developed cerebral oedema those who received mannitol had a significantly better survival than those who did not receive it (47.1% and 5.9% respectively, p 0.008, Fisher's one-tail test).

UI MeSH Term Description Entries
D008297 Male Males
D008353 Mannitol A diuretic and renal diagnostic aid related to sorbitol. It has little significant energy value as it is largely eliminated from the body before any metabolism can take place. It can be used to treat oliguria associated with kidney failure or other manifestations of inadequate renal function and has been used for determination of glomerular filtration rate. Mannitol is also commonly used as a research tool in cell biological studies, usually to control osmolarity. (L)-Mannitol,Osmitrol,Osmofundin
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D001929 Brain Edema Increased intracellular or extracellular fluid in brain tissue. Cytotoxic brain edema (swelling due to increased intracellular fluid) is indicative of a disturbance in cell metabolism, and is commonly associated with hypoxic or ischemic injuries (see HYPOXIA, BRAIN). An increase in extracellular fluid may be caused by increased brain capillary permeability (vasogenic edema), an osmotic gradient, local blockages in interstitial fluid pathways, or by obstruction of CSF flow (e.g., obstructive HYDROCEPHALUS). (From Childs Nerv Syst 1992 Sep; 8(6):301-6) Brain Swelling,Cerebral Edema,Cytotoxic Brain Edema,Intracranial Edema,Vasogenic Cerebral Edema,Cerebral Edema, Cytotoxic,Cerebral Edema, Vasogenic,Cytotoxic Cerebral Edema,Vasogenic Brain Edema,Brain Edema, Cytotoxic,Brain Edema, Vasogenic,Brain Swellings,Cerebral Edemas, Vasogenic,Edema, Brain,Edema, Cerebral,Edema, Cytotoxic Brain,Edema, Cytotoxic Cerebral,Edema, Intracranial,Edema, Vasogenic Brain,Edema, Vasogenic Cerebral,Swelling, Brain
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003907 Dexamethasone An anti-inflammatory 9-fluoro-glucocorticoid. Hexadecadrol,Decaject,Decaject-L.A.,Decameth,Decaspray,Dexasone,Dexpak,Hexadrol,Maxidex,Methylfluorprednisolone,Millicorten,Oradexon,Decaject L.A.
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006501 Hepatic Encephalopathy A syndrome characterized by central nervous system dysfunction in association with LIVER FAILURE, including portal-systemic shunts. Clinical features include lethargy and CONFUSION (frequently progressing to COMA); ASTERIXIS; NYSTAGMUS, PATHOLOGIC; brisk oculovestibular reflexes; decorticate and decerebrate posturing; MUSCLE SPASTICITY; and bilateral extensor plantar reflexes (see REFLEX, BABINSKI). ELECTROENCEPHALOGRAPHY may demonstrate triphasic waves. (From Adams et al., Principles of Neurology, 6th ed, pp1117-20; Plum & Posner, Diagnosis of Stupor and Coma, 3rd ed, p222-5) Encephalopathy, Hepatic,Portosystemic Encephalopathy,Encephalopathy, Hepatocerebral,Encephalopathy, Portal-Systemic,Encephalopathy, Portosystemic,Fulminant Hepatic Failure with Cerebral Edema,Hepatic Coma,Hepatic Stupor,Hepatocerebral Encephalopathy,Portal-Systemic Encephalopathy,Coma, Hepatic,Comas, Hepatic,Encephalopathies, Hepatic,Encephalopathies, Hepatocerebral,Encephalopathies, Portal-Systemic,Encephalopathies, Portosystemic,Encephalopathy, Portal Systemic,Hepatic Comas,Hepatic Encephalopathies,Hepatic Stupors,Hepatocerebral Encephalopathies,Portal Systemic Encephalopathy,Portal-Systemic Encephalopathies,Portosystemic Encephalopathies,Stupor, Hepatic,Stupors, Hepatic

Related Publications

J Canalese, and A E Gimson, and C Davis, and P J Mellon, and M Davis, and R Williams
Cerebral oedema of fulminant hepatic failure.
October 1983, Clinical science (London, England : 1979),
J Canalese, and A E Gimson, and C Davis, and P J Mellon, and M Davis, and R Williams
Cerebral oedema in fulminant hepatic failure.
January 1996, Nursing in critical care,
J Canalese, and A E Gimson, and C Davis, and P J Mellon, and M Davis, and R Williams
Controlled hyperventilation in the prevention of cerebral oedema in fulminant hepatic failure.
January 1986, Journal of hepatology,
J Canalese, and A E Gimson, and C Davis, and P J Mellon, and M Davis, and R Williams
Glycerol therapy for cerebral oedema complicating fulminant hepatic failure.
June 1975, British medical journal,
J Canalese, and A E Gimson, and C Davis, and P J Mellon, and M Davis, and R Williams
Cerebral oedema and monitoring of intracranial pressure in fulminant hepatic failure.
April 1982, Gastroenterologia Japonica,
J Canalese, and A E Gimson, and C Davis, and P J Mellon, and M Davis, and R Williams
Early death from paracetamol (acetaminophen) induced fulminant hepatic failure without cerebral oedema.
October 2003, Journal of hepatology,
J Canalese, and A E Gimson, and C Davis, and P J Mellon, and M Davis, and R Williams
Controlled trial of antithrombin III supplementation in fulminant hepatic failure.
March 1993, Journal of hepatology,
J Canalese, and A E Gimson, and C Davis, and P J Mellon, and M Davis, and R Williams
Control of cerebral oedema by total hepatectomy and extracorporeal liver support in fulminant hepatic failure.
October 1993, Lancet (London, England),
J Canalese, and A E Gimson, and C Davis, and P J Mellon, and M Davis, and R Williams
Controlled trial of glycerol versus dexamethasone in the treatment of cerebral oedema in acute cerebral infarction.
May 1975, Lancet (London, England),
J Canalese, and A E Gimson, and C Davis, and P J Mellon, and M Davis, and R Williams
Mannitol in neonatal cerebral oedema.
January 1990, Brain & development,
Copied contents to your clipboard!